Medical Devices

To Enhance Cancer Drugs & Address Untreatable Infectious Disease Disorders

 

Novel Strategies to Maximize the Benefit of Drug Therapies

ImmunePrep™ and ChemoPrep™ are designed to optimize the targeted delivery of therapeutic antibodies and cancer chemotherapies. Whereas, ChemoPure™ reflects our vision for diminishing the toxicity of chemotherapy.

Our Company
$250 Billion

The size of the global market for therapeutic antibodies and cancer chemotherapies in 2022.*

Source

*World Health Organization, Data Bridge Market Research

Sigyn Therapy in Action
Sigyn Therapy in Action

Targeting Unmet Needs in Global Health

We designed Sigyn Therapy™ to address infectious disease disorders that are not treatable with drugs.  Our opportunities include untreatable viral pathogens, antibiotic-resistant bacterial infections, endotoxemia and sepsis.

Infectious Disease Disorders

Our Criterion for Strategic Innovation

"We create medical technologies with two attributes in mind:  they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."

Jim Joyce
Chairman and CEO Inventor

                                                                                                                                                              

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today

Stock Information